\nTurn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and nine months ended September 30, 2026.<\/p>\n
Additional Stage 1\/Phase 2a results show encouraging response in the full atopic dermatitis trial population<\/b><\/p>\n
\nIn October 2026, Turn Therapeutics reported additional results from the full intent-to-treat population of its 50-patient Stage 1 trial of GX-03 in atopic dermatitis. The analysis includes all 50 patients assigned to treatment in the trial. After four weeks, 59.3% of patients treated with GX-03 achieved clear or almost clear skin, compared with 30.4% of patients receiving vehicle, a difference of 28.8 percentage points. Additionally, 40.7% of GX-03 patients achieved EASI-100 at Week 8, compared with 17.4% receiving vehicle. The Eczema Area and Severity Index (EASI) measures how much skin is affected by eczema and how severe the visible signs are; EASI-100 means no visible eczema remained. These findings show encouraging responses at both four and eight weeks.<\/p>\n
\n\u201cThe results from our full Stage 1 trial population give us an important look at how patients responded to GX-03 across a wide range of disease severity and extent,\u201d said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. \u201cWe took what we learned from the initial trial and used it to refine our ongoing Phase 2b trial.\u201d<\/p>\n
\nThe Stage 1\/Phase 2a results also show improved separation between GX-03 and vehicle arm. Among patients who entered the trial with severe itch, 61.5% of those treated with GX-03 achieved clear or almost clear skin after four weeks, compared with 8.3% receiving vehicle. Additionally, 46.2% of GX-03 patients with severe itch achieved EASI-100 at Week 8, compared with 8.3% receiving vehicle.<\/p>\n
\nThe ongoing Phase 2b trial is evaluating GX-03 in 120\u2013136 atopic dermatitis patients with severe itch (pp-NRS><\/span>7), across a range of skin involvement (EASI><\/span>1.1). The trial compares GX-03 with an ointment vehicle and measures how many patients achieve clear or almost clear skin, as well as improvement in disease extent and severity as measured by EASI. To date, the Phase 2b trial has recorded no patient dropouts. In the Phase 2a trial, the dropout rate was below 5%, with no treatment-related discontinuations. These rates are well below the attrition typically seen in trials of this kind, reflecting the program\u2019s favorable tolerability. Turn Therapeutics expects to report topline results from the Phase 2b trial in the first quarter of 2027.<\/p>\n \n\u201cThe completed Stage 1 trial gives us a clearer picture of GX-03\u2019s potential, particularly for patients with severe itching. We believe severe itch may also help strengthen confidence in an atopic dermatitis diagnosis, since other skin conditions can look similar on visual examination alone,\u201d said Robert R. Redfield, M.D., Chief Scientific Officer of Turn Therapeutics. \u201cOur Phase 2b trial is designed to find out whether those results can be repeated in a larger group of patients.\u201d<\/p>\n Turn Therapeutics accelerates Phase 2a trial of GX-03 in hidradenitis suppurativa<\/b><\/p>\n \nWe are also accelerating patient enrollment in the planned Phase 2a trial of GX-03 for hidradenitis suppurativa (HS) which is now expected to begin in the first quarter of 2027, ahead of the previously announced second-quarter target. HS is a chronic, often debilitating inflammatory skin disease that causes painful lumps, abscesses, and, in more advanced cases, tunnels beneath the skin. It affects an estimated 900,0001 <\/sup>adults in the U.S. The approximately 80-patient trial will compare GX-03 with a matched ointment placebo, assessing its effect on active inflammatory lesions and symptoms such as pain at both early and later timepoints.<\/p>\n \nThe trial will be designed to evaluate the safety and efficacy of GX-03 in patients with HS. GX-03 is designed to combine anti-inflammatory activity with the bacterial membrane-disrupting properties of its proprietary formulation. This dual approach may be particularly relevant to HS, where bacteria may contribute to persistent inflammation and recurrent lesions. By potentially addressing both processes directly at the affected skin, GX-03 could offer patients a differentiated, non-systemic treatment option. Treatment duration and assessment timepoints are being finalized.<\/p>\n \nWith HS enrollment beginning and our Phase 2b atopic dermatitis trial moving forward, we expect the first quarter of 2027 to be a very active time for Turn.<\/p>\n Onychomycosis program<\/b><\/p>\n \nOnychomycosis, commonly known as nail fungus, affects an estimated 10% of the general population and up to 50% of adults over 702<\/sup>. GX-03 has shown that it can penetrate the nail and reduce fungal burden in animal studies which, coupled with independent investigator-sponsored human evidence, supports its continued development to test its efficacy as a potential topical treatment for fungal nail infections. Turn Therapeutics plans to share more about the next steps in onychomycosis as its atopic dermatitis and HS programs move forward.<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20261109969887\/en\/2963584\/3\/TTRX_BIG-cdd6b828_%281%29.jpg\")
<\/td>\n<\/tr>\n